GNTA
What one share of Genenta Science S.p.A. holds
Biological Products, (No Diagnostic Substances)
TEMs, which normally have an affinity for and travel to tumors, into a “Trojan Horse” to counteract cancer progression and prevent tumor relapse. Because our technology is not target-dependent, we believe it can be used for treatment across a broad variety of cancers.
Genenta Science S.p.A.’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Profit | −$0.37 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.39 |
| Cash and investments | $1.41 |
| Book value | $1.09 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$0.43 | $0.00 | −$0.55 | — | $2.41 |
| 2022 | — | −$0.49 | $0.00 | −$0.43 | — | $1.83 |
| 2023 | — | −$0.69 | $0.00 | −$0.67 | — | $1.24 |
| 2024 | — | −$0.53 | $0.00 | −$0.37 | — | $0.71 |
| 2025 | — | −$0.37 | $0.00 | −$0.39 | — | $1.09 |